Dova Pharmaceuticals Inc (NASDAQ:DOVA) – Jefferies Group decreased their FY2022 earnings per share (EPS) estimates for Dova Pharmaceuticals in a research note issued to investors on Thursday. Jefferies Group analyst E. Yang now anticipates that the company will post earnings per share of $3.97 for the year, down from their prior forecast of $4.03. Jefferies Group has a “Buy” rating and a $33.00 price objective on the stock.
Other equities research analysts have also issued reports about the company. BidaskClub upgraded Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Zacks Investment Research lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $32.75.
Dova Pharmaceuticals (DOVA) traded down $1.85 during trading hours on Monday, hitting $32.86. The stock had a trading volume of 108,040 shares, compared to its average volume of 92,332. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). During the same period in the previous year, the business earned ($0.44) earnings per share.
Large investors have recently bought and sold shares of the company. Fosun International Ltd increased its stake in shares of Dova Pharmaceuticals by 9.2% in the 3rd quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock worth $17,239,000 after purchasing an additional 60,000 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Dova Pharmaceuticals in the 2nd quarter worth $668,000. Wells Fargo & Company MN increased its stake in shares of Dova Pharmaceuticals by 62.1% in the 3rd quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock worth $7,874,000 after purchasing an additional 124,287 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Dova Pharmaceuticals in the 2nd quarter worth $382,000. Finally, Perceptive Advisors LLC increased its stake in Dova Pharmaceuticals by 2.8% in the 3rd quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock worth $42,587,000 after buying an additional 47,516 shares in the last quarter. Hedge funds and other institutional investors own 26.93% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Dova Pharmaceuticals Inc Expected to Post FY2022 Earnings of $3.97 Per Share (DOVA)” was reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.thestockobserver.com/2018/02/21/dova-pharmaceuticals-inc-expected-to-post-fy2022-earnings-of-3-97-per-share-dova.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.